BIOMARIN PHARMACEUTICAL INC (BMRN)

Import this data to Google Sheets with:

=jivedata("BMRN","financials")

Full statements spill as a table. For one cell: =jivedata("BMRN","Revenue") or =jivedata("BMRN","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

BIOMARIN PHARMACEUTICAL INC

BMRN • CIK 0001048477

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$158,097	$484,214	$409,478	$149,258
Investment Income, Interest	$58,339	$74,883	$74,904	$70,104
InterestExpenseNonoperating	—	$12,666	$10,899	$83,610
Other Operating Income (Expense), Net	$-10,538	$-4,668	$8,997	$13,358
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$188,563	$541,763	$482,480	$149,110
Income Tax Expense (Benefit)	$20,918	$114,904	$133,579	$76,138
Net Income (Loss) Attributable to Parent	$167,645	$426,859	$348,901	$72,972
Weighted Average Number of Shares Outstanding, Basic	187,834,000	190,027,000	191,787,000	193,306,000
Weighted Average Number of Shares Outstanding, Diluted	191,595,000	196,708,000	197,394,000	194,898,000
Revenue from Contract with Customer, Excluding Assessed Tax	$2,419,226	$2,853,915	$3,221,253	$3,406,614
Cost of Revenue	$514,854	$580,235	$717,442	$813,588
Research and Development Expense	$746,773	$747,184	$921,930	$987,639
Selling, General and Administrative Expense	$937,291	$1,009,025	$1,153,017	$1,368,461
Amortization of Intangible Assets	—	$43,257	$19,386	$87,668
Gain (Loss) on Disposition of Assets	$0	$10,000	$0	$0
Costs and Expenses	$2,261,129	$2,369,701	$2,811,775	$3,257,356
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,407,000	9,438,000	11,307,000	17,017,000

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$755,127	$942,842	$1,311,679	$874,005
Debt Securities, Available-for-sale, Current	$318,683	$194,864	$248,930	$0
Accounts Receivable, after Allowance for Credit Loss, Current	$633,704	$660,535	$908,214	$1,061,047
Assets	$6,841,603	$6,988,940	$7,594,022	$11,723,442
Inventory, Net	$1,107,183	$1,232,653	$1,298,883	$1,782,524
Other Assets, Current	$141,391	$201,533	$185,784	$254,047
Assets, Current	$2,956,088	$3,232,427	$3,953,490	$3,971,623
Debt Securities, Available-for-sale, Noncurrent	$611,135	$521,238	$492,242	$0
Property, Plant and Equipment, Net	$1,066,133	$1,043,041	$952,508	$989,994
Intangible Assets, Net (Excluding Goodwill)	$294,701	$255,278	$213,837	$4,879,367
Liabilities	$1,890,054	$1,330,950	$1,507,023	$5,401,750
Goodwill	$196,199	$196,199	$196,199	$655,745
Deferred Income Tax Assets, Net	$1,545,809	$1,489,366	$1,508,697	$888,575
Other Assets, Noncurrent	$171,538	$251,391	$277,049	$338,138
Accounts Payable and Accrued Liabilities, Current	$683,147	$606,988	$759,031	$1,005,793
Liabilities, Current	$1,177,024	$606,988	$759,031	$1,663,996
Convertible Debt, Noncurrent	$593,095	$595,138	$597,176	$597,176
Other Liabilities, Noncurrent	$119,935	$128,824	$150,816	$209,815
Common Stock, Value, Issued	$189	$191	$192	$194
Additional Paid in Capital, Common Stock	$5,611,562	$5,802,068	$5,956,582	$6,037,019
Common Stock Issued, Employee Stock Trust	$9,860	$11,227	$10,508	$11,233
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-28,788	$61,653	$-13,473	$-8,783
Retained Earnings (Accumulated Deficit)	$-621,554	$-194,695	$154,206	$304,495
Stockholders' Equity Attributable to Parent	$4,951,549	$5,657,990	$6,086,999	$6,321,692
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000	500,000,000
Common Stock, Shares, Issued	188,598,154	190,761,349	192,300,101	193,535,556

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$167,645	$426,859	$348,901	$72,972
Net Cash Provided by (Used in) Operating Activities	$159,259	$572,841	$827,994	$857,089
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$1,308	$4,830	$-2,521	$328
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$30,596	$187,715	$368,837	$-339,811
Depreciation, Depletion and Amortization	$104,386	$96,426	$79,557	$152,974
Payments to Acquire Property, Plant, and Equipment	$96,691	$85,424	$103,038	$118,908
Amortization of Debt Issuance Costs and Discounts	$4,188	$3,359	$2,622	$29,214
Proceeds from Sale, Maturity and Collection of Investments	$864,863	$633,018	$337,801	$909,340
Accretion (Amortization) of Discounts and Premiums, Investments	$9,228	$8,345	$4,801	$3,894
Payments to Acquire Investments	$868,496	$410,250	$355,875	$179,234
Share-based Payment Arrangement, Noncash Expense	$207,099	$201,571	$181,409	$215,330
Gain (Loss) on Disposition of Assets	$0	$10,000	$0	$0
Payments to Acquire Intangible Assets	$10,920	$11,994	$7,937	$13,104
Asset Impairment Charges	$38,608	—	$125,012	$122,045
Inventory Write-down	—	—	$119,208	$119,208
Payments for (Proceeds from) Other Investing Activities	$0	$-1,141	$0	$-4,966
Deferred Income Tax Expense (Benefit)	$-44,981	$56,096	$48,738	$-10,772
Net Cash Provided by (Used in) Investing Activities	$-111,244	$136,491	$-414,242	$-4,749,763
Foreign Currency Transaction Gain (Loss), Unrealized	$-28,446	$16,753	$-4,459	$-5,719
Research and Development Asset Acquired Other than Through Business Combination, Written-off	—	—	$220,963	$220,963
Other Noncash Income (Expense)	$365	$-20,135	$4,414	$8,032
Increase (Decrease) in Accounts Receivable	$190,435	$57,909	$228,054	$117,935
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised	$69,353	$49,277	$14,460	$13,408
Increase (Decrease) in Inventories	$157,058	$63,530	$116,929	$32,133
Payment, Tax Withholding, Share-based Payment Arrangement	$76,319	$77,560	$55,965	$44,380
Increase (Decrease) in Other Current Assets	$50,335	$3,778	$-8,891	$-394
Repayments of Convertible Debt	—	$494,987	$0	$0
Increase (Decrease) in Other Noncurrent Assets	$31,149	$73,700	$38,573	$16,063
Proceeds from (Payments for) Other Financing Activities	$0	$-3,177	$-889	$-889
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$68,853	$-32,240	$66,136	$89,290
Net Cash Provided by (Used in) Financing Activities	$-18,727	$-526,447	$-42,394	$3,552,535
Increase (Decrease) in Other Operating Liabilities	$23,585	$14,761	$14,869	$15,999
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$755,127	$942,842	$1,311,679	$3,335,311
Interest Paid, Excluding Capitalized Interest, Operating Activities	$10,303	$10,361	$7,245	$7,324
Income Taxes Paid	$73,312	$57,269	$96,205	$87,324

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("BMRN","financials")

Full statements spill as a table. For one cell: =jivedata("BMRN","Revenue") or =jivedata("BMRN","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.